3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Tumor-Agnostic
1
Thoracic
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
Cyclophosphamide
170
Rituximab
143
Specimen Handling
82
venetoclax
79
fludarabine
79
obinutuzumab
67
Vincristine
67
Doxorubicin
65
Biopsy
64
Prednisone
63
Magnetic Resonance Spectroscopy
63
zanubrutinib
52
Lenalidomide
52
Dexamethasone
48
Cytarabine
43
Methotrexate
42
blinatumomab
40
Immunotherapy, Adoptive
38
acalabrutinib
37
Bendamustine Hydrochloride
37
Etoposide
32
fludarabine phosphate
31
ibrutinib
28
glofitamab
28
polatuzumab vedotin
26
pirtobrutinib
24
orelabrutinib
24
Gemcitabine
23
Injections
21
pembrolizumab
18
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Cobicistat
×
Lymphoid
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA